130 related articles for article (PubMed ID: 35077082)
21. Biallelic MYH germline mutations as cause of Muir-Torre syndrome.
Guillén-Ponce C; Castillejo A; Barberá VM; Pascual-Ramírez JC; Andrada E; Castillejo MI; Guarinós C; Molina-Garrido MJ; Carrato A; Soto JL
Fam Cancer; 2010 Jun; 9(2):151-4. PubMed ID: 19998059
[TBL] [Abstract][Full Text] [Related]
22. Somatic MMR gene mutations as a cause for MSI-H sebaceous neoplasms in Muir-Torre syndrome-like patients.
Joly MO; Attignon V; Saurin JC; Desseigne F; Leroux D; Martin-Denavit T; Giraud S; Bonnet-Dupeyron MN; Faivre L; Auclair J; Grand-Masson C; Audoynaud C; Wang Q
Hum Mutat; 2015 Mar; 36(3):292-5. PubMed ID: 25504677
[TBL] [Abstract][Full Text] [Related]
23. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract][Full Text] [Related]
24. Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome.
Harper HL; McKenney JK; Heald B; Stephenson A; Campbell SC; Plesec T; Magi-Galluzzi C
Mod Pathol; 2017 Jan; 30(1):146-156. PubMed ID: 27713421
[TBL] [Abstract][Full Text] [Related]
25. Clinical characterization and mutation spectrum in Caribbean Hispanic families with Lynch syndrome.
Cruz-Correa M; Diaz-Algorri Y; Pérez-Mayoral J; Suleiman-Suleiman W; Gonzalez-Pons Mdel M; Bertrán C; Casellas N; Rodríguez N; Pardo S; Rivera K; Mosquera R; Rodriguez-Quilichini S
Fam Cancer; 2015 Sep; 14(3):415-25. PubMed ID: 25782445
[TBL] [Abstract][Full Text] [Related]
26. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.
Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
[TBL] [Abstract][Full Text] [Related]
27. A novel complex mutation in MSH2 contributes to both Muir-Torre and Lynch Syndrome.
Perera S; Ramyar L; Mitri A; Pollett A; Gallinger S; Speevak MD; Aronson M; Bapat B
J Hum Genet; 2010 Jan; 55(1):37-41. PubMed ID: 19911012
[TBL] [Abstract][Full Text] [Related]
28. MSH6, Past and Present and Muir-Torre Syndrome-Connecting the Dots.
Mahalingam M
Am J Dermatopathol; 2017 Apr; 39(4):239-249. PubMed ID: 28323777
[TBL] [Abstract][Full Text] [Related]
29. Retroperitoneal undifferentiated pleomorphic sarcoma having microsatellite instability associated with Muir-Torre syndrome: case report and review of literature.
Lee N; Luthra R; Lopez-Terrada D; Wang WL; Lazar AJ
J Cutan Pathol; 2013 Aug; 40(8):730-3. PubMed ID: 23672746
[TBL] [Abstract][Full Text] [Related]
30. Lynch syndrome with exclusive skin involvement: time to consider a molecular definition?
Vaisfeld A; Calicchia M; Pomponi MG; Lucci-Cordisco E; Reggiani-Bonetti L; Genuardi M
Fam Cancer; 2019 Oct; 18(4):421-427. PubMed ID: 31292797
[TBL] [Abstract][Full Text] [Related]
31. First case report of Muir-Torre syndrome associated with non-small cell lung cancer.
Nolan L; Eccles D; Cross E; Crawford G; Beck N; Bateman A; Ottensmeier C
Fam Cancer; 2009; 8(4):359-62. PubMed ID: 19449129
[TBL] [Abstract][Full Text] [Related]
32. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome.
Chhibber V; Dresser K; Mahalingam M
Mod Pathol; 2008 Feb; 21(2):159-64. PubMed ID: 18065960
[TBL] [Abstract][Full Text] [Related]
33. Pseudomyxoma peritonei of a mature ovarian teratoma caused by mismatch repair deficiency in a patient with Lynch syndrome: a case report.
Gohda Y; Noguchi R; Horie T; Igari T; Nakamura H; Ohta Y; Yamaguchi K; Ikenoue T; Hatakeyama S; Yusa N; Furukawa Y; Yano H
BMC Med Genet; 2016 Dec; 17(1):94. PubMed ID: 27938333
[TBL] [Abstract][Full Text] [Related]
34. An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome.
Nguyen CV; Gaddis KJ; Stephens MR; Seykora JT; Chu EY
JAMA Dermatol; 2020 Jun; 156(6):676-680. PubMed ID: 32267475
[TBL] [Abstract][Full Text] [Related]
35. Synchronous gastric and sebaceous cancers, a rare manifestation of MLH1-related Muir-Torre syndrome.
Svec J; Schwarzová L; Janošíková B; Stekrová J; Mandys V; Kment M; Vodička P
Int J Clin Exp Pathol; 2014; 7(8):5196-202. PubMed ID: 25197397
[TBL] [Abstract][Full Text] [Related]
36. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome.
Roberts ME; Riegert-Johnson DL; Thomas BC; Rumilla KM; Thomas CS; Heckman MG; Purcell JU; Hanson NB; Leppig KA; Lim J; Cappel MA
Genet Med; 2014 Sep; 16(9):711-6. PubMed ID: 24603434
[TBL] [Abstract][Full Text] [Related]
37. Role of microsatellite instability, immunohistochemistry and mismatch repair germline aberrations in immunosuppressed transplant patients: a phenocopy dilemma in Muir-Torre syndrome.
Ponti G; Manfredini M; Pellacani G; Tomasi A
Clin Chem Lab Med; 2016 Nov; 54(11):1725-1731. PubMed ID: 27016151
[TBL] [Abstract][Full Text] [Related]
38. Review of the current medical literature and assessment of current utilization patterns regarding mismatch repair protein immunohistochemistry in cutaneous Muir-Torre syndrome-associated neoplasms.
Lee JB; Litzner BR; Vidal CI
J Cutan Pathol; 2017 Nov; 44(11):931-937. PubMed ID: 28749576
[TBL] [Abstract][Full Text] [Related]
39. Muir-Torre Syndrome: expanding the genotype and phenotype--a further family with a MSH6 mutation.
Murphy HR; Armstrong R; Cairns D; Greenhalgh KL
Fam Cancer; 2008; 7(3):255-7. PubMed ID: 18236172
[TBL] [Abstract][Full Text] [Related]
40. Muir-Torre syndrome: a case of unusual coexisting genetic mutations.
Cino D; Drumm C; Sheahan K; D'Arcy C; Nolan N; Hoti E; Winter D; O'Duffy F; Dolan R; Moriarty B
Clin Exp Dermatol; 2022 Mar; 47(3):602-604. PubMed ID: 34762321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]